483
Polpharma Biologics S.APolpharma Biologics S.A – FDA 483
Record Details
The FDA inspection of Polpharma Biologics S.A. in Gdańsk, Poland, revealed multiple significant deficiencies in their drug substance manufacturing processes. Key issues include inadequate process validation, insufficient cleaning and disinfection controls, and a lack of proper documentation for changes and investigations. These observations indicate a need for comprehensive improvements in quality systems and operational procedures.
- Company
- Polpharma Biologics S.A
- Product type
- biologics
View Company Profile
ID · 65f8ead4-a181-44df-83a1-b88e007e7454
Other documents for Polpharma Biologics S.A
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.